Brilinta DaYu Study

PHASE4CompletedINTERVENTIONAL
Enrollment

2,004

Participants

Timeline

Start Date

June 26, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Ticagrelor

90mg/tablet, 1 tablet bid

Trial Locations (39)

100006

Research Site, Beijing

100029

Research Site, Beijing

100037

Research Site, Beijing

100050

Research Site, Beijing

100083

Research Site, Beijing

100730

Research Site, Beijing

110001

Research Site, Shenyang

110016

Research Site, Shenyang

130021

Research Site, Changchun

130041

Research Site, Chuangchun

200025

Research Site, Shanghai

200433

Research Site, Shanghai

210009

Research Site, Nanjing

210012

Research Site, Nanjing

210029

Research Site, Nanjing

214023

Research Site, Wuxi

221006

Research Site, Xuzhou

250012

Research Site, Jinan

250021

Research Site, Jinan

250033

Research Site, Jinan

272011

Research Site, Jining

350001

Research Site, Fuzhou

361004

Research Site, Xiamen

450000

Research Site, Zhengzhou

450012

Research Site, Zhengzhou

510080

Research Site, Guangzhou

510220

Research Site, Guangzhou

518003

Research Site, Shenzhen

518020

Research Site, Shenzhen

518036

Research Site, Shenzhen

528403

Research Site, Zhongshan

610041

Research Site, Chengdu

650032

Research Site, Kunming

710032

Research Site, Xi'an

710061

Research Site, Xi'an

Unknown

Research Site, Fuzhou

Research Site, Shanghai

030001

Research Site, Taiyuan

CN-430022

Research Site, Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY